ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Systemic sclerosis"

  • Abstract Number: 1661 • ACR Convergence 2022

    Osteoclastogenesis and Vascular Endothelial Growth Factor Blood Levels in Patients with Systemic Sclerosis with and Without Calcinosis Cutis

    Antonia Valenzuela1, Guillermo Perez2, Carolina Iturriaga2 and Rebeca Montalva2, 1Pontificia Universidad Catolica de Chile, Santiago, Chile, 2Pontificia Universidad Catolica de Chile, Santiago de Chile, Chile

    Background/Purpose: Calcinosis cutis is a debilitating complication of systemic sclerosis (SSc) with no effective treatments. Although the pathogenesis of SSc-related calcinosis remains unknown, there is…
  • Abstract Number: 2178 • ACR Convergence 2022

    BNT162b2 mRNA Vaccine Against Covid 19, Humoral Response, Safety and Efficacy in Scleroderma Patients

    Yolanda Braun-Moscovici1, Marielle Kaplan1, Maya Braun2, Doron Markovits3, Sami Giryes3, Kohava Toledano3, Yonit Tavor3, Katya Dolnikov3, Rula Daood3 and Alexandra Balbir-Gurman4, 1Rambam Health Care Campus and Rappaport Faculty of Medicine, Haifa, Israel, 2Hebrew University of Jerusalem, Bioinformatics, Jerusalem, Israel, 3Rambam Health Care Campus, Haifa, Israel, 4Rheumatology Institute, Rambam Health Care Campus, Haifa, Israel

    Background/Purpose: In the begining of pandemic and till spring 2021 there were no clinical and laboratory data regarding sefety and efficacy of mRNA vaccines against…
  • Abstract Number: 1048 • ACR Convergence 2022

    Nailfold Capillaroscopy and Candidate Biomarker Levels in Systemic Sclerosis-associated Pulmonary Hypertension, Profiling of Non-invasive Markers: A Cross Sectional Study

    Jacqueline Lemmers1, Arjan van Caam2, Brigit Kersten2, Els Ende, van den2, Hanneke KNAAPEN2, Arie Dijk, van2, Wanda Hagmolen of ten Have2, Frank van den Hoogen2, Hans Koenen2, Sander van Leuven3, wynand Alkema4, Ruben Smeets2 and Madelon Vonk5, 1Radboud University Medical Centre Nijmegen, Nijmegen, Netherlands, 2Radboudumc, Nijmegen, Netherlands, 3Radboud University, Nijmegen, Netherlands, 4Hanze University, Groningen the Netherlands, Dept. Data Science for Life Sciences & Health, Groningen, Netherlands, 5Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands

    Background/Purpose: Pulmonary hypertension (PH) is one of the leading causes of death in Systemic Sclerosis (SSc). Early detection and treatment of PH in SSc is…
  • Abstract Number: 1177 • ACR Convergence 2022

    Identification of a New Type of Pro-phagocytic Macrophages in Patients with Systemic Sclerosis

    Amela Hukara1, Tracy Tabib2, Michal Rudnik1, Oliver Distler3, Przemyslaw Blyszczuk1, Robert Lafyatis2 and Gabriela Kania1, 1Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 2Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 3Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland

    Background/Purpose: Phagocytosis is a crucial cellular process, which under certain immuno-pathological conditions can be activated in macrophages in an uncontrolled manner. Biomarker studies have implicated…
  • Abstract Number: 1523 • ACR Convergence 2022

    Anti-RNPC3 Autoantibodies in Mixed Connective Tissue Disease Are Associated with Systemic Sclerosis Skin Involvement

    Darya S. Jalaledin1, Hajar El Kamouni2, Alexandra Albert3, Sabrina Hoa4, Josiane Bourre-Tessier5, Eric Rich5, Jean-Richard Goulet6, Martial Koenig7, Minoru Satoh8, Marvin Fritzler9, May Choi10, Yves Troyanov11, Jean-Luc Senécal, MD12 and Océane Landon-Cardinal5, 1Division of Internal Medicine, Centre Hospitalier de l'Université de Sherbrooke, Saint-Lambert, Canada, 2Division of Rheumatology, Centre Hospitalier de l'Université de Montréal, Laval, Canada, 3Division of Rheumatology, Centre Hospitalier de l'Université Laval, Québec, QC, Canada, 4University of Montreal, Montréal, QC, Canada, 5Division of Rheumatology, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, 6Division of Rheumatology, Centre Hospitalier de l'Université de Montréal, Saint-Lambert, Canada, 7Division of Internal Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, 8Department of Human, Information and Science, University of Occupational Environmental Health, Kitakyusyu Fukuoka, Japan, 9University of Calgary, Calgary, AB, Canada, 10Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, 11Division of Rheumatology, Hôpital du Sacré-Coeur de Montréal, Montréal, QC, Canada, 12Division of Rheumatology, Centre Hospitalier de l'Université de Montréal, Montréal, Canada

    Background/Purpose: RNA-binding region containing 3 (RNPC3) protein acts as a molecular bridge, promoting U11/U12 RNP complex formation. In previous studies, systemic sclerosis (SSc) patients who…
  • Abstract Number: 1672 • ACR Convergence 2022

    The Impact of Systemic Sclerosis (SSc) on Women’s Health Evaluated with a New SSc-specific Patient-reported Questionnaire

    Maria Grazia Lazzaroni1, Liala Moschetti1, Eleonora Pedretti1, Andrea Lojacono2, Francesca Ramazzotto3, Cristina Zanardini3, Zatti Sonia3, Angela Tincani4, Franco Franceschini1, Paolo Airò5 and Laura Andreoli1, 1Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, 2Obstetrics and Gynecology, ASST Garda, Desenzano del Garda, Brescia, Brescia, Italy, 3Obstetrics and Gynecology, ASST Spedali Civili and University of Brescia, Brescia, Italy, 4Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Gussago, Italy, 5Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia, Italy

    Background/Purpose: Systemic Sclerosis (SSc) has a strong female predominance and can significantly impair the everyday quality of life of patients. We aimed at designing a…
  • Abstract Number: 2189 • ACR Convergence 2022

    Impact of a Fatigue and Energy Management Program for Persons with Systemic Sclerosis (FAME-iSS): A Pilot Study

    Janet Poole1, Deirdre Connolly2, Jessica Salazar3 and Kristine Carandang4, 1University of New Mexico, Albuquerque, NM, 2School of Medicine, Trinity College, Dublin, Ireland, 3University of New Mexico, Occupational Therapy Graduate Program, Albuquerque, NM, 4Young Patients' Autoimmune Research & Empowerment Alliance, San Diego, CA

    Background/Purpose: Fatigue is one of the most prevalent and disabling symptom reported by people with systemic sclerosis (SSc). No fatigue-specific programs exist for people with…
  • Abstract Number: 1049 • ACR Convergence 2022

    Risk Stratification of Patients with Systemic Sclerosis-associated Pulmonary Arterial Hypertension in EUSTAR Using the Current and New Proposed Criteria

    Hilde Jenssen Bjørkekjær1, cosimo bruni2, PATRICIA E CARREIRA3, Paolo Airò4, CARMEN PILAR SIMEON5, Marie-Elise Truchetet6, Alessandro Giollo7, Alexandra Balbir-Gurman8, Mickaël MARTIN9, Chris Denton10, Armando Gabrielli11, Håvard Fretheim12, Imon Barua12, Helle Bitter13, Øyvind Midtvedt12, Kaspar Broch14, Arne Andreassen12, Yoshiya Tanaka15, Gabriela Riemekasten16, Ulf Müller-Ladner17, Marco Matucci-Cerinic2, Ivan Castellvi18, Elise Siegert19, Eric Hachulla20, Oliver Distler21 and Anna-Maria Hoffmann-Vold12, 1Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, Kristiansand, Norway, 2University of Florence, Florence, Italy, 3HOSPITAL 12 DE OCTUBRE, Madrid, Spain, 4Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia, Italy, 5Hospital Vall D'Hebron, Barcelona, Spain, 6CHU de Bordeaux, Bordeaux, France, 7Rheumatology Section, Department of Medicine, University of Verona, Italy, Verona, Italy, 8Rheumatology Institute, Rambam Health Care Campus, Haifa, Israel, 9Poitiers's Universatory Hospital, Department of Internal Medicine, Poitiers, France, Mignaloux-Beauvoir, France, 10University College London, London, United Kingdom, 11Università Politecnica delle Marche, Ancona, Italy, 12Oslo University Hospital, Oslo, Norway, 13Sorlandet sykehus, Kristiansand, Norway, 14Oslo University Hospital, Rikshospitalet, Department of Cardiology, Oslo, Norway, Oslo, Norway, 15University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, 16University Clinic Schleswit-Holstein (UKSH), Luebeck, Germany, 17JLU Campus KK, Bad Nauheim, Germany, 18Hospital Universitari de la Santa Creu i Sant Pau, Vilafranca del Pened, Spain, 19Charité Hospital, Berlin, Germany, 20University of Lille, LILLE, France, 21Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland

    Background/Purpose: Pulmonary arterial hypertension (PAH) is a major clinical challenge in systemic sclerosis (SSc). A new definition for precapillary PH is proposed. Risk stratification is…
  • Abstract Number: 1178 • ACR Convergence 2022

    Key Features of Human Fibrosing Interstitial Lung Disease Are Captured in a Preclinical Mouse Model upon Repetitive, but Not Single Intratracheal Bleomycin Dosing

    David Lauer1, Janine Schniering2, Matthias Brunner1, Chantal Meier3, Kerstin Klein1, Oliver Distler4 and Britta Maurer1, 1Department of Rheumatology and Immunology, University Hospital Bern, University of Bern, Bern, Switzerland, 2Helmholtz Zentrum München, Institute of Lung Health and Immunity (LHI), Comprehensive Pneumonology Center, Munich, Germany, 3Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland, 4Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland

    Background/Purpose: Repetitive alveolar epithelial injury together with dysregulated tissue repair is crucial for the transition of acute self-limiting to chronic-persisting inflammation and fibrosis in fibrosing…
  • Abstract Number: 1524 • ACR Convergence 2022

    Risk Factors for Lung Function Decline in Systemic Sclerosis Interstitial Lung Disease in a Large Single-Center Cohort

    Ahmad Ramahi1, Alain Lescoat2, David Roofeh1, Vivek Nagaraja1, Rajaie Namas3, Suiyuan Huang1, John Varga1, David O’Dwyer1, Bonnie Wang1, Kevin Flaherty1, Ella Kazerooni1 and Dinesh Khanna4, 1University of Michigan, Ann Arbor, MI, 2CHU Rennes - University Rennes 1, Rennes, France, 3Medical Subspecialties Institute, Division of Rheumatology at Cleveland Clinic, Abu Dhabi, United Arab Emirates, 4Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI

    Background/Purpose: Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is the leading cause of scleroderma-related mortality. This work identifies factors associated with SSc-ILD decline on pulmonary function…
  • Abstract Number: 1731 • ACR Convergence 2022

    Systemic Sclerosis-Associated Class II HLA Alleles Restrict the Diversity of the CDR3 and the T Cell Receptor Repertoire in African American Patients

    Urvashi Kaundal1, Chloe Borden1, Cihan Oguz2, Jinghua Lu2, Emilee Stenson1, Ami Shah3, Maureen Mayes4, Ayo Doumatey5, Amy Bentley5, Daniel Shriner5, Robyn Domsic6, Thomas Medsger7, Paula Ramos8, Richard Silver8, Virginia Steen9, John Varga10, Vivien Hsu11, Lesley Ann Saketkoo12, Elena Schiopu13, Dinesh Khanna14, Jessica Gordon15, Lindsey Criswell16, Heather Gladue17, Chris Derk18, Elana Bernstein19, S. Louis Bridges, Jr.15, Victoria Shanmugam20, Lorinda Chung21, Suzanne Kafaja22, Reem Jan23, Marcin Trojanowski24, Avram Goldberg25, Benjamin Korman26, Settara Chandrasekharappa5, Faiza Naz27, Stefania Dell'Orso1, Adebowale Adeyemo5, Charles Rotimi5, Elaine Remmers5, Francesco Boin28, Fredrick Wigley29, Peter Sun2, Daniel Kastner5 and Pravitt Gourh30, 1National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 2National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 3Johns Hopkins Rheumatology, Baltimore, MD, 4Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, 5National Human Genome Research Institute, Bethesda, MD, 6University of Pittsburgh, Pittsburgh, PA, 7University of Pittsburgh School of Medicine, Pittsburgh, PA, 8Medical University of South Carolina, Charleston, SC, 9Georgetown University School of Medicine, Washington, DC, 10University of Michigan, Ann Arbor, MI, 11Rutgers-RWJ Medical School, South Plainfield, NJ, 12University Medical Center - Comprehensive Pulmonary Hypertension Center and ILD Clinic Programs // New Orleans Scleroderma and Sarcoidosis Patient Care & Research Centeris, New Orleans, LA, 13Michigan Medicine, Ann Arbor, MI, 14Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, 15Hospital for Special Surgery, New York, NY, 16National Human Genome Research Institute, NIH, Bethesda, MD, 17Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, 18University of Pennsylvania, Philadelphia, PA, 19Columbia University, New York, NY, 20George Washington University, Great Falls, VA, 21Stanford University, Stanford, CA, 22UCLA Department of Medicine, Division of Rheumatology, Los Angeles, CA, 23University of Chicago, Chicago, IL, 24Boston University School of Medicine, Boston, MA, 25NYU Langone Medical Center - NYU Hospital for Joint Diseases, Lake Success, NY, 26University of Rochester, Rochester, NY, 27National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 28Cedars-Sinai Medical Center, Los Angeles, CA, 29Johns Hopkins University, Baltimore, MD, 30National Institutes of Health, Bethesda, MD

    Background/Purpose: Systemic sclerosis (SSc) is an autoimmune, fibrotic disorder that disproportionately affects African Americans (AA). Previous work from our lab and others has suggested a…
  • Abstract Number: 2190 • ACR Convergence 2022

    Characterizing Compensatory Cognitive Strategy Use in People with Systemic Sclerosis

    Yen Chen1, Alain Lescoat2, Dinesh Khanna3 and Susan Murphy4, 1University of Michigan, Ann Arbor, MI, 2CHU Rennes - University Rennes 1, Rennes, France, 3Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, 4University of Michigan, Grosse Ile, MI

    Background/Purpose: Individuals with systemic sclerosis (SSc) report cognitive problems that worsen symptoms and daily activity performance. Compensatory cognitive strategies (CCS) are commonly taught to help…
  • Abstract Number: 1050 • ACR Convergence 2022

    Clinically Recognized Depression and Mental Health Treatment in a Single Center Cohort of Patients with Systemic Sclerosis

    Marissa Savoie1, Alexandra Poeschla1, na lu2, Yuqing Zhang3, Marcy Bolster1, Sara Schoenfeld1 and Flavia Castelino1, 1Massachusetts General Hospital, Boston, MA, 2Arthritis Research Canada, Boston, MA, 3Massachusetts General Hospital, Quincy, MA

    Background/Purpose: The prevalence of depression among patients with systemic sclerosis (SSc) is 35-65%1, yet little is known about mental health care utilization in SSc. It…
  • Abstract Number: 1179 • ACR Convergence 2022

    Single Cell RNA Sequencing Analysis of Cryopreserved versus Fresh Skin Biopsy Samples from Systemic Sclerosis Patients and Healthy Controls

    Brian Skaug1, Marka Lyons1, Julio Charles1, Maureen Mayes2 and Shervin Assassi3, 1University of Texas McGovern Medical School at Houston, Houston, TX, 2Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, 3McGovern Medical School, University of Texas, Houston, TX

    Background/Purpose: Single cell RNA Sequencing (scRNA-Seq) can elucidate tissue-resident cell populations and gene expression profiles with unprecedented granularity. Application of this approach to systemic sclerosis…
  • Abstract Number: 1526 • ACR Convergence 2022

    Developing a Screening Tool for the Detection of Interstitial Lung Disease in Systemic Sclerosis: The ILD-RISC Risk Score

    cosimo bruni1, Lorenzo Tofani1, Håvard Fretheim2, Sophie Liem3, Arthiha Velauthapillai4, Hilde Jenssen Bjørkekjær5, Imon Barua2, Ilaria Galetti6, Alexandru Garaiman7, Mike Becker7, Anna-Maria Hoffmann-Vold2, Jeska de Vries-Bouwstra8, Madelon Vonk9, Jörg Distler10, Marco Matucci-Cerinic1 and Oliver Distler7, 1University of Florence, Florence, Italy, 2Oslo University Hospital, Oslo, Norway, 3LUMC, Leiden, Netherlands, 4Radboud University Medical Center, Nijmegen, Nijmegen, Netherlands, 5Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, Kristiansand, Norway, 6Gruppo Italiano Lotta alla Sclerodermia (GILS), Milano, Italy, 7Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 8Leiden University Medical Center, Leiden, Netherlands, 9Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, 10Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany

    Background/Purpose: High resolution computed tomography (HRCT) is the gold standard for the diagnosis of systemic sclerosis associated interstitial lung disease (SSc-ILD). Although there is agreement…
  • « Previous Page
  • 1
  • …
  • 18
  • 19
  • 20
  • 21
  • 22
  • …
  • 46
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology